Swiss National Bank
OCUL icon

Swiss National Bank’s Ocular Therapeutix OCUL Stock Holding History

Swiss National Bank’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3M Sell
305,800
-7,500
-2% -$68K ﹤0.01% 1713
2026
Q1 		$2.65M Hold
313,300
– – ﹤0.01% 1710
2025
Q4 		$3.8M Buy
313,300
+112,600
+56% +$1.37M ﹤0.01% 1505
2025
Q3 		$2.35M Buy
200,700
+3,300
+2% +$39.5K ﹤0.01% 1774
2025
Q2 		$1.83M Buy
197,400
+13,400
+7% +$105K ﹤0.01% 1850
2025
Q1 		$1.35M Hold
184,000
– – ﹤0.01% 1988
2024
Q4 		$1.57M Sell
184,000
-13,900
-7% -$136K ﹤0.01% 1986
2024
Q3 		$1.72M Hold
197,900
– – ﹤0.01% 1950
2024
Q2 		$1.35M Buy
+197,900
New +$1.22M ﹤0.01% 2015
2022
Q2 		– Sell
-172,100
Closed -$852K – 2773
2022
Q1 		$852K Buy
172,100
+12,100
+8% +$67.1K ﹤0.01% 2470
2021
Q4 		$1.11M Buy
160,000
+16,700
+12% +$130K ﹤0.01% 2421
2021
Q3 		$1.43M Buy
143,300
+2,200
+2% +$24.7K ﹤0.01% 2244
2021
Q2 		$2M Buy
141,100
+2,500
+2% +$38K ﹤0.01% 2094
2021
Q1 		$2.27M Buy
138,600
+1,500
+1% +$28.9K ﹤0.01% 1922
2020
Q4 		$2.84M Buy
+137,100
New +$2.04M ﹤0.01% 1708
2016
Q4 		– Sell
-19,000
Closed -$131K – 2569
2016
Q3 		$131K Hold
19,000
– – ﹤0.01% 2529
2016
Q2 		$94K Buy
19,000
+2,200
+13% +$21.8K ﹤0.01% 2578
2016
Q1 		$156K Buy
16,800
+3,800
+29% +$28.8K ﹤0.01% 2578
2015
Q4 		$122K Hold
13,000
– – ﹤0.01% 2629
2015
Q3 		$183K Buy
13,000
+2,200
+20% +$44.2K ﹤0.01% 2506
2015
Q2 		$227K Buy
+10,800
New +$268K ﹤0.01% 2524

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Swiss National Bank's OCUL Position: Q2 2026 in Review

Swiss National Bank reduced its Ocular Therapeutix (OCUL) stake by 2.4% in Q2 2026, selling an estimated $68K and leaving 305,800 shares worth $3M. The position accounts for ﹤0.01% of the portfolio, ranked #1713.

Swiss National Bank first reported a position in OCUL in Q2 2015 and has held it in 21 quarters since. The position peaked at $3.8M in Q4 2025. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Swiss National Bank held 305,800 shares of Ocular Therapeutix worth $3M as of Q2 2026.
  • Swiss National Bank sold 7,500 Ocular Therapeutix shares in Q2 2026, an estimated $68K.
  • Ocular Therapeutix made up ﹤0.01% of Swiss National Bank's portfolio in Q2 2026, its #1713 holding.
  • Swiss National Bank first reported a position in Ocular Therapeutix in Q2 2015 and has held it in 21 quarters since.
  • Swiss National Bank's Ocular Therapeutix position peaked at $3.8M in Q4 2025.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.